PDCD1 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), most commonly programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) inhibitors, have revolutionized the treatment and significantly improved the survival of patients with advanced non-small-cell lung cancer (NSCLC).